Recent studies have demonstrated that exogenous A2 fragments ameliorate the coagulation function in posttraumatic brain injury by competitively binding to endogenous VWF-A1 [18], highlighting the therapeutic potential of targeting the A1/A2 interface. The gene discussed is VWF; the disease is injury.